CA3244694A1 - SOLID FORMS OF GUSACITINIB - Google Patents
SOLID FORMS OF GUSACITINIBInfo
- Publication number
- CA3244694A1 CA3244694A1 CA3244694A CA3244694A CA3244694A1 CA 3244694 A1 CA3244694 A1 CA 3244694A1 CA 3244694 A CA3244694 A CA 3244694A CA 3244694 A CA3244694 A CA 3244694A CA 3244694 A1 CA3244694 A1 CA 3244694A1
- Authority
- CA
- Canada
- Prior art keywords
- theta
- degrees
- gusacitinib
- crystalline
- peaks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202211009506 | 2022-02-23 | ||
| IN202211009506 | 2022-02-23 | ||
| IN202211028117 | 2022-05-16 | ||
| IN202211028117 | 2022-05-16 | ||
| IN202211031922 | 2022-06-03 | ||
| IN202211031922 | 2022-06-03 | ||
| IN202211053997 | 2022-09-21 | ||
| IN202211053997 | 2022-09-21 | ||
| IN202311006675 | 2023-02-02 | ||
| IN202311006675 | 2023-02-02 | ||
| IN202311007408 | 2023-02-06 | ||
| IN202311007408 | 2023-02-06 | ||
| PCT/US2023/013668 WO2023164024A1 (en) | 2022-02-23 | 2023-02-23 | Solid state forms of gusacitinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3244694A1 true CA3244694A1 (en) | 2023-08-31 |
Family
ID=85640884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3244694A Pending CA3244694A1 (en) | 2022-02-23 | 2023-02-23 | SOLID FORMS OF GUSACITINIB |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250171448A1 (https=) |
| EP (1) | EP4482836A1 (https=) |
| JP (1) | JP2025506783A (https=) |
| KR (1) | KR20240151808A (https=) |
| CA (1) | CA3244694A1 (https=) |
| WO (1) | WO2023164024A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202510870A (zh) * | 2023-07-27 | 2025-03-16 | 美商自由生物有限公司 | Jak/syk抑制劑之組合物及固體形式 |
| WO2025020171A1 (en) * | 2023-07-27 | 2025-01-30 | Libertas Bio, Inc. | Crystalline forms of a jak/syk inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2748166T3 (pl) * | 2011-08-23 | 2019-05-31 | Asana Biosciences Llc | Związki pirimido-pirydazynonowe oraz ich zastosowanie |
| WO2018187294A1 (en) * | 2017-04-03 | 2018-10-11 | Asana Biosciences, Llc | Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof |
| EP3875078A1 (en) * | 2020-03-06 | 2021-09-08 | Dompe' Farmaceutici S.P.A. | Compounds for the treatment of covid-19 |
-
2023
- 2023-02-23 KR KR1020247030857A patent/KR20240151808A/ko active Pending
- 2023-02-23 EP EP23711320.4A patent/EP4482836A1/en active Pending
- 2023-02-23 JP JP2024549676A patent/JP2025506783A/ja active Pending
- 2023-02-23 US US18/839,779 patent/US20250171448A1/en active Pending
- 2023-02-23 WO PCT/US2023/013668 patent/WO2023164024A1/en not_active Ceased
- 2023-02-23 CA CA3244694A patent/CA3244694A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023164024A1 (en) | 2023-08-31 |
| KR20240151808A (ko) | 2024-10-18 |
| EP4482836A1 (en) | 2025-01-01 |
| JP2025506783A (ja) | 2025-03-13 |
| US20250171448A1 (en) | 2025-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240246949A1 (en) | Solid state forms of lanifibranor and process for preparation thereof | |
| US11220488B2 (en) | Crystalline polymorph of Ponesimod | |
| WO2023076205A1 (en) | Solid state forms of ensifentrine and process for preparation thereof | |
| US20240199578A1 (en) | Solid state forms of zavegepant and process for preparation thereof | |
| US20250171448A1 (en) | Solid state forms of gusacitinib | |
| EP4271678A1 (en) | Solid state forms of capivasertib and process for preparation thereof | |
| WO2024180474A1 (en) | Solid state forms of sabizabulin and process for preparation thereof | |
| EP4508035A1 (en) | Solid state forms of mavacamten and process for preparation thereof | |
| WO2023163964A1 (en) | Solid state forms of seltorexant | |
| US20230103724A1 (en) | Solid state forms of avapritinib and process for preparation thereof | |
| WO2021216628A1 (en) | Solid state forms of trifarotene and process for preparation thereof | |
| US20220153744A1 (en) | Solid state forms of acalabrutinib | |
| US20240246914A1 (en) | Solid state form of centanafadine hcl and process for preparation thereof | |
| US20250361221A1 (en) | Solid state forms of paltusotine and process for preparation thereof | |
| EP4051659B1 (en) | Solid state forms of fezagepras and process for preparation thereof | |
| US20240173304A1 (en) | Solid state forms of tideglusib and process for preparation thereof | |
| US20230357163A1 (en) | Solid state forms of gefapixant and process for preparation thereof | |
| WO2025017530A1 (en) | Solid state forms of buntanetap and process for preparation thereof | |
| WO2025210540A1 (en) | Solid state forms of camlipixant and process for preparation thereof | |
| WO2025219948A1 (en) | Crystalline forms of govorestat | |
| WO2025078973A1 (en) | Solid state forms of linerixibat and process for preparation thereof | |
| EP4673223A1 (en) | Solid state forms of anlotinib and process for preparation thereof | |
| WO2025257758A1 (en) | Solid state forms of navacaprant | |
| WO2021025969A1 (en) | Solid state forms of berotralstat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240820 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240823 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240823 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240823 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241125 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241223 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250123 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250123 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250123 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250212 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20250711 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250711 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250724 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250804 |